FIELD: chemical-pharmaceutical industry; medicine.
SUBSTANCE: present invention relates to development of anti-inflammatory drugs. Disclosed is a chemical compound—tetrasubstituted with glycolic acid piceatannol (E)-2,2'-((4-(3,5-bis(carboxylatomethoxy)styryl)-1,2-phenylene)bis(oxy)) diacetate: 
. Also disclosed is a pharmaceutical composition, comprising an active substance in the form of said chemical compound or a pharmaceutically acceptable salt form thereof and pharmaceutically acceptable excipients, and its use for treating acute respiratory distress syndrome.
EFFECT: invention enables to obtain a pharmaceutical composition which is used to treat systemic inflammatory diseases and conditions, such as acute respiratory distress syndrome.
5 cl, 5 dwg, 13 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL AGENT FOR CHRONIC WOUND THERAPY | 2018 |
|
RU2701737C1 |
| COMPOSITION OF TRADITIONAL CHINESE MEDICINE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2806632C1 |
| REMEDY WITH ANTI-TUMOR EFFECT FOR TREATMENT OF ONCOLOGICAL DISEASES | 2018 |
|
RU2761429C2 |
| NOVEL CRYSTALLINE FORM OF N,N'-BIS-[2-(1N-IMIDAZOL-4-YL)ETHYL]PROPANEDIAMIDE AND PHARMACEUTICAL USE THEREOF | 2022 |
|
RU2823162C2 |
| METHOD FOR PREVENTING GASTRIC ULCERS USING A MEDICINAL AGENT BASED ON A LOW MOLECULAR WEIGHT PHENOL COMPOUND IN EXPERIMENT | 2018 |
|
RU2696205C1 |
| PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY ACTION | 2022 |
|
RU2801579C1 |
| METHOD OF CORRECTION OF STREPTOZOTOCIN-INDUCED DIABETES MELLITUS IN RATS USING A HETEROCYCLIC AMIDE-BASED DRUG | 2018 |
|
RU2687979C1 |
| APPLICATION OF AN ALPHA1-PROTEINASE INHIBITOR (ALPHA1-ANTITRYPSIN) FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND METHOD FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME USING ALPHA1-ANTITRYPSIN | 2020 |
|
RU2757875C1 |
| PROLONGED ACTION PHARMACEUTICAL COMPOSITION BASED ON 5-ETHOXY-2-[2-(MORPHOLINO)-ETHYLTHIO]BENZIMIDAZOLE DIHYDROCHLORIDE AND/OR BASE (APHOBAZOLUM) | 2017 |
|
RU2694837C2 |
| PHARMACEUTICAL COMPOSITION BASED ON BIS-(N-MONOSUCCINYL-L-SERYL-L-LYSINE) HEXAMETHYLENEDIAMIDE (GSB-106) | 2018 |
|
RU2697254C1 |
